Business Wire9h
U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that the U.S. Food and Drug Administration (FDA) ...
Agios Pharmaceuticals: Liver Toxicity Issues May Threaten Thalassemia Approval (Rating Downgrade)
Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.
Woman's World on MSN12h
These Fatty Liver Treatment Tips Boost Your Metabolism and Energy
Your liver plays crucial roles in filtering toxins, converting food into fuel, strengthening immunity and keeping blood sugar ...
Orthopedics This Week1d
When Surgery Isn’t an Option, This Knee Tumor May Still Be Treated
Your patient presents with pain, swelling and impaired knee function. One rare diagnosis is non-malignant tenosynovial giant ...
Guardian molecule keeps cells on track: New perspectives for the treatment of liver cancer
A guardian molecule ensures that liver cells do not lose their identity. This has been discovered by researchers from the ...
Korea Joongang Daily on MSN5d
Olix, Eli Lilly to develop liver disease drug under $630 million deal
Olix Pharmaceuticals signed a $630 million licensing deal with Eli Lilly to develop treatments for cardiovascular and ...